article thumbnail

Scientists Sue DEA as it Drags its Feet and Hampers Cannabis Research

WeedAdvisor

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety.

DEA 111
article thumbnail

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. Orphan Drug Designation?

DEA 66
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA CBD Regulations Are On the Way (Sorta)

Canna Law Blog

There has been so much talk from the Food and Drug Administration (“FDA”) around cannabidiol (“CBD”) regulations that it makes one’s head spin. For years everyone has wondered when, or even if , the FDA would propose and adopt CBD regulations. A little CBD history. The future of FDA CBD regulations.

CBD 78
article thumbnail

CBD: Everything You Need to Know

CannaMD

In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. So sit back, relax – and if you can’t relax, grab some CBD! What is CBD? Let’s clear up one of the biggest sources of confusion right off the bat: CBD is a cannabis compound called cannabidiol.

CBD 105
article thumbnail

Approval of Epidiolex Validates What Many CBD Users Already Knew

MedicalJane

On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). ” Using CBD Oil To Treat Seizures. Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree. The Next Move Is On The DEA.

article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

Drug Enforcement Agency (DEA). According to the company’s CEO, George Hodgin, “federally legal FDA- and DEA-approved cannabis-based drugs will absolutely upend the traditional pharmaceutical market.”. CBD is also contained in another FDA-approved medicine called Epidiolex®.

article thumbnail

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA.